GeoVax Labs, Inc. New (GOVX) Stock Price

GOVXStock

$0.24−98.30%52W

Market Cap$2.41M

P/E—

PEG Ratio—

Div yield—

Beta3.90

GOVX Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-92.12%

Price vs S&P 500 (4W)-32.24%

VGM Score37.55

Book Value / Share (Quarterly)$0.24

P/TBV (Annual)3.90x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)212.58%

Cash Flow / Share (Quarterly)$-2.67

Price vs S&P 500 (YTD)-106.36%

Gross Margin (TTM)-31.76%

Net Profit Margin (TTM)-403.80%

EPS (TTM)$-13.92

10-Day Avg Trading Volume1.64M

EPS Excl Extra (TTM)$-13.92

Revenue Growth (5Y)6.42%

EPS (Annual)$-22.40

ROI (Annual)-561.15%

Gross Margin (Annual)25.00%

Net Profit Margin (5Y Avg)-4735.50%

Cash / Share (Quarterly)$0.43

ROA (Last FY)-338.46%

Revenue Growth TTM (YoY)-84.76%

EBITD / Share (TTM)$-8.98

ROE (5Y Avg)-397.04%

Operating Margin (TTM)-407.34%

Cash Flow / Share (Annual)$-13.17

P/B Ratio1.37x

P/B Ratio (Quarterly)2.51x

Net Income / Employee (Annual)$-1,129,700

EV / Revenue (TTM)-0.12x

Net Interest Coverage (TTM)-19.93x

ROA (TTM)-394.73%

EPS Incl Extra (Annual)$-22.40

Current Ratio (Annual)2.74x

Quick Ratio (Quarterly)1.16x

3-Month Avg Trading Volume0.70M

52-Week Price Return-98.30%

Revenue / Employee (TTM)$0

Tangible BV / Share (Quarterly)$0.34

P/S Ratio (Annual)0.97x

Asset Turnover (Annual)0.39x

52-Week High$15.75

Operating Margin (5Y Avg)-4738.15%

EPS Excl Extra (Annual)$-22.40

CapEx CAGR (5Y)-29.34%

Tangible BV CAGR (5Y)-20.70%

26-Week Price Return-82.22%

Quick Ratio (Annual)1.59x

13-Week Price Return-75.54%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)1.54x

Enterprise Value$-735,900

Revenue / Share Growth (5Y)-33.36%

Asset Turnover (TTM)0.69x

Book Value / Share Growth (5Y)-43.21%

Revenue / Employee (Annual)$131,000

Inventory Turnover (Annual)5.36x

Pretax Margin (Annual)-862.33%

Cash / Share (Annual)$1.78

3-Month Return Std Dev85.40%

Gross Margin (5Y Avg)-920.72%

Net Income / Employee (TTM)$-1,075,000

ROE (Last FY)-561.15%

Net Interest Coverage (Annual)-2781.44x

EPS Basic Excl Extra (Annual)$-22.40

P/FCF (TTM)5.89x

Receivables Turnover (TTM)7.55x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-13.92

Receivables Turnover (Annual)7.55x

ROI (TTM)-743.66%

P/S Ratio (TTM)0.39x

Pretax Margin (5Y Avg)-4735.50%

Revenue / Share (Annual)$2.60

Tangible BV / Share (Annual)$1.01

Price vs S&P 500 (52W)-113.84%

Year-to-Date Return-94.43%

5-Day Price Return-15.59%

EPS Normalized (Annual)$-22.40

ROA (5Y Avg)-225.35%

Net Profit Margin (Annual)-862.33%

Month-to-Date Return-28.67%

Cash Flow / Share (TTM)$-0.90

EBITD / Share (Annual)$-22.51

Operating Margin (Annual)-869.33%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-397.04%

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-13.92

P/TBV (Quarterly)3.90x

P/B Ratio (Annual)1.34x

Inventory Turnover (TTM)5.82x

Pretax Margin (TTM)-403.80%

Book Value / Share (Annual)$2.21

Price vs S&P 500 (13W)-78.22%

Beta3.90x

P/FCF (Annual)15.05x

Revenue / Share (TTM)$0.00

ROE (TTM)-743.66%

52-Week Low$0.23

vGradeB

gGradeD

mGradeF

vgmGradeD

GOVX Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Jul 27, 2026	-$2.15	-$0.97	+54.99%(+$1.18)
Q1 2026	May 14, 2026	-$0.84	-$2.62	-210.06%(-$1.78)
Q3 2025	Nov 13, 2025	-$6.63	-$7.75	-16.98%(-$1.13)
Q2 2025	Jul 28, 2025	-$9.00	-$8.75	+2.78%(+$0.25)

GOVX Analyst Recommendations

Jun 2026

Jul 2026

Aug 2026

Sep 2026

4.13

Industry Peers — Pharmaceuticals(574)

Symbol	Value Score	Growth Score	Momentum Score	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
GOVXGeoVax Labs, Inc. New	B	D	F	0.4x	-84.8%	-31.8%	—	$0.24
LLYEli Lilly & Co.	D	B	A	14.9x	49.6%	83.4%	27.6%	$1257.03
JNJJohnson & Johnson	D	C	B	6.2x	7.8%	67.7%	14.9%	$255.56
ABBVABBVIE INC.	D	C	A	7.8x	10.4%	72.8%	-2.9%	$285.42
MRKMerck & Co., Inc.	D	C	A	5.4x	4.6%	77.3%	21.2%	$145.95
NVSNovartis AG	C	C	B	4.9x	3.3%	75.0%	15.3%	$150.62
AZNAstraZeneca PLC	C	B	B	4.3x	8.6%	81.3%	21.9%	$165.41
ABTAbbott Laboratories	C	C	B	3.9x	8.1%	56.8%	8.2%	$104.89
NVONovo-Nordisk A/S	B	C	C	3.5x	5.6%	80.7%	20.7%	$38.83
PFEPfizer Inc.	C	D	A	2.6x	-0.2%	74.7%	-3.5%	$29.58
VRTXVertex Pharmaceuticals Inc	D	C	B	10.1x	10.2%	86.0%	8.3%	$499.74
BMYBristol-Myers Squibb Co.	B	B	B	2.5x	3.1%	71.7%	—	$59.75
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	C	C	B	2.3x	5.0%	73.6%	-0.5%	$49.51
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	D	B	1.8x	13.4%	72.8%	-8.2%	$40.61
REGNRegeneron Pharmaceuticals Inc	C	C	A	5.2x	9.3%	86.0%	6.3%	$790.74
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	A	2.1x	3.1%	65.5%	-12.6%	$19.67
TEVATeva Pharmaceutical Industries Limited	D	C	A	2.8x	4.1%	52.9%	—	$41.50
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	B	6.3x	31.1%	88.5%	—	$369.06
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	A	13.8x	10.0%	—	-12.1%	$60.96
ZTSZOETIS INC.	C	C	B	3.5x	1.4%	71.6%	12.0%	$79.38
ALNYAlnylam Pharmaceuticals, Inc.	D	A	C	6.5x	95.1%	79.7%	—	$231.83
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	3215.5x	-67.6%	81.2%	—	$33.53
UTHRUnited Therapeutics Corp	C	C	B	7.2x	2.5%	86.1%	19.3%	$533.12
GMABGenmab A/S ADS	D	C	A	5.5x	22.3%	93.0%	6.8%	$37.00
VTRSViatris Inc. Common Stock	B	C	A	1.5x	4.4%	40.3%	—	$18.66
INSMInsmed, Inc.	F	A	C	18.5x	185.8%	83.5%	—	$96.27
ASNDAscendis Pharma A/S Ordinary Share	D	A	B	11.9x	113.3%	91.3%	—	$225.25
JAZZJazz Pharmaceuticals, Inc.	B	C	B	3.0x	12.6%	88.4%	-1.4%	$210.23
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	18.2x	202.4%	94.4%	—	$66.39
CORTCorcept Therapeutics Inc.	F	C	A	14.3x	16.0%	98.3%	-0.5%	$110.16
ELANElanco Animal Health Incorporated Common Stock	D	B	B	2.3x	11.9%	55.4%	29.9%	$23.55
SMMTSummit Therapeutics Inc. Common Stock	F	—	C	12187.5x	—	—	—	$14.63
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	C	B	3.1x	-0.9%	61.4%	16.5%	$13.07
BMRNBioMarin Pharmaceuticals Inc	C	C	B	3.1x	11.2%	79.6%	-17.0%	$54.68
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	8.1x	149.0%	91.5%	—	$449.74
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	213.8x	2928.4%	—	—	$84.95
CYTKCytokinetics Inc.	F	D	B	127.3x	-21.1%	—	—	$61.95
PTGXProtagonist Therapeutics, Inc	F	B	B	29.5x	34.8%	—	—	$128.75
TGTXTG Therapeutics, Inc.	D	B	B	10.3x	76.1%	82.4%	—	$53.97
AXSMAxsome Therapeutics, Inc	D	B	C	10.6x	56.9%	93.2%	—	$157.14
ARWRArrowhead Research Corporation	D	A	C	11.8x	16.9%	—	—	$55.90
ABVXAbivax SA American Depositary Shares	—	—	C	—	—	—	—	$88.13
SYRESpyre Therapeutics, Inc. Common Stock	—	—	B	5995.2x	—	—	—	$79.90
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	8.2x	-7.5%	98.2%	—	$42.94
ALKSAlkermes Inc. plc	D	C	B	4.1x	10.8%	84.6%	—	$41.22
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	789.2x	—	—	—	$241.76
AMRXAmneal Pharmaceuticals, Inc. Class A Common Stock	D	C	A	2.0x	9.3%	39.3%	-18.4%	$19.18
KNSAKiniksa Pharmaceuticals International, plc Class A Ordinary Shares	D	B	A	7.3x	58.9%	89.8%	—	$78.59
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	24.7x	53.5%	70.9%	—	$86.17
LGNDLigand Pharmaceuticals Inc.	D	B	B	20.3x	54.9%	95.4%	—	$295.54
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	—	—	—	—	$142.78

About GeoVax Labs, Inc. New

GeoVax Labs is a clinical-stage biotechnology company developing vaccines and immunotherapies for infectious diseases and solid tumors using proprietary platforms. Its lead program, GEO-CM04S1, is a next-generation COVID-19 vaccine in human trials, complemented by candidates targeting Monkeypox, hemorrhagic fevers, Zika, and head and neck cancer. The company's approach combines preventive vaccines and gene-directed immunotherapies across a diversified pipeline.